NBC Securities Inc. Sells 207 Shares of Amgen Inc. (NASDAQ:AMGN)

NBC Securities Inc. reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 3.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,472 shares of the medical research company’s stock after selling 207 shares during the period. NBC Securities Inc.’s holdings in Amgen were worth $2,085,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Fisher Asset Management LLC grew its holdings in shares of Amgen by 4.0% during the 4th quarter. Fisher Asset Management LLC now owns 78,753 shares of the medical research company’s stock valued at $22,682,000 after purchasing an additional 3,049 shares during the last quarter. ICA Group Wealth Management LLC acquired a new position in shares of Amgen during the fourth quarter worth $188,000. Leo Wealth LLC acquired a new stake in shares of Amgen during the 4th quarter valued at $449,000. Nomura Holdings Inc. acquired a new position in Amgen in the 4th quarter worth about $3,104,000. Finally, Duncan Williams Asset Management LLC bought a new position in Amgen in the first quarter valued at about $590,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on AMGN. Truist Financial downgraded Amgen from a “buy” rating to a “hold” rating and upped their price objective for the company from $320.00 to $333.00 in a research note on Monday. Wells Fargo & Company downgraded shares of Amgen from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $320.00 to $335.00 in a research note on Wednesday, August 7th. Morgan Stanley reduced their price objective on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 11th. Oppenheimer reaffirmed an “outperform” rating and set a $380.00 target price on shares of Amgen in a research report on Wednesday, August 7th. Finally, Robert W. Baird reiterated an “underperform” rating and issued a $215.00 price target on shares of Amgen in a research report on Wednesday, September 25th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Amgen has an average rating of “Hold” and a consensus target price of $326.95.

Amgen Stock Up 0.5 %

Shares of AMGN traded up $1.57 during trading hours on Tuesday, hitting $326.19. The stock had a trading volume of 470,133 shares, compared to its average volume of 2,452,321. The firm has a 50 day simple moving average of $326.05 and a 200-day simple moving average of $311.20. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The firm has a market capitalization of $174.98 billion, a P/E ratio of 46.37, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The firm had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. During the same quarter in the prior year, the firm earned $5.00 EPS. The company’s revenue was up 20.1% compared to the same quarter last year. Sell-side analysts predict that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.76%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.